Pub Date : 2018-02-19DOI: 10.15406/JDMDC.2018.05.00133
N. G. Tavsanli, Seçil Köken, S. Akıncıoğlu, Havva Artuvan, Zeynep Nerse
In WHO rankings, diabetes has been recognized as being in the group of rapidly increasing epidemiological diseases [1]. It was found that there were 400 million adult diabetics in the world in 2015, and this number is predicted to rise to over 640 million by 2040. Seventy-five percent of diabetics in the world live in medium and low income countries, and five million people in the world die of diabetes each year. The cost of medical care for diabetic individuals is more than 670 billion dollars annually according to the IDF [2]. According to the results of a 2010 study by Diabetes Epidemiology in Turkey (TURDEP II), the prevalence of diabetes is 13.7%, the prevalence of obesity is 32%, and the prevalence of hypertension is 30% [3].
{"title":"Results of scanning for diabetes, obesity and blood pressure: a sample from manisa in western turkey","authors":"N. G. Tavsanli, Seçil Köken, S. Akıncıoğlu, Havva Artuvan, Zeynep Nerse","doi":"10.15406/JDMDC.2018.05.00133","DOIUrl":"https://doi.org/10.15406/JDMDC.2018.05.00133","url":null,"abstract":"In WHO rankings, diabetes has been recognized as being in the group of rapidly increasing epidemiological diseases [1]. It was found that there were 400 million adult diabetics in the world in 2015, and this number is predicted to rise to over 640 million by 2040. Seventy-five percent of diabetics in the world live in medium and low income countries, and five million people in the world die of diabetes each year. The cost of medical care for diabetic individuals is more than 670 billion dollars annually according to the IDF [2]. According to the results of a 2010 study by Diabetes Epidemiology in Turkey (TURDEP II), the prevalence of diabetes is 13.7%, the prevalence of obesity is 32%, and the prevalence of hypertension is 30% [3].","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"16 1","pages":"20-24"},"PeriodicalIF":0.0,"publicationDate":"2018-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81701475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-19DOI: 10.15406/JDMDC.2018.05.00132
P. Guness
{"title":"An experience in recreational diabetic day in a non-governmental organisation, t1 diams, in Mauritius","authors":"P. Guness","doi":"10.15406/JDMDC.2018.05.00132","DOIUrl":"https://doi.org/10.15406/JDMDC.2018.05.00132","url":null,"abstract":"","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"2 1","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2018-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78076268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-24DOI: 10.15406/jdmdc.2018.05.00131
P. Ranasinghe, P. Galappatthy, P. Katulanda, R. Jayawardena, C. D. Pathiranage, A. Lionel, G. Constantine
Zinc is an essential trace element that plays a vital role as a co-factor in enzyme action, cell membrane stabilization, gene expression and cell signaling [1]. It is also important in insulin action and carbohydrate metabolism [2]. Zinc is involved in the physiology of insulin at several stages; it is found in the insulin secretory granules and is known to participate in the insulin synthesis, stabilization of pro-insulin, insulin secretion, insulin sensitivity, and insulin degradation [3,4]. Zinc could also play a role in the pathogenesis of diabetes. Studies have shown that diabetes is accompanied by hypozincemia and hyperzincuria [5,6]. Zinc absorption is also know to be altered in patients with diabetes [7]. The altered Zinc absorption and hyperzincuria identified in patients with diabetes is an indication of either the fact that Zinc metabolism is altered as a result of diabetes or the altered Zinc metabolism plays a role in the pathogenesis of diabetes. Homeostasis of Zinc is thought to depend on absorption as well as excretion. Studies have shown that the Zinc ingested by healthy persons are eliminated in the feces (90%) and in urine (2–10%) [8]. Zinc is primarily absorbed from small intestine, duodenum and ileum [9]. The oral Zinc tolerance test was proved to be an acceptable method to study zinc absorption and excretion in humans [10]. Absorption and/ or excretion of Zinc may be altered in various pathological states, such as diabetes mellitus. Pre-diabetes is an intermediate state of hyperglycemia with glycaemic parameters above normal but below the threshold for the initiation of treatment for diabetes [11]. The pre-diabetic state is characterized by either impaired Volume 5 Issue 1 2018
{"title":"Pharmacokinetics of zinc in pre-diabetes: a pilot study","authors":"P. Ranasinghe, P. Galappatthy, P. Katulanda, R. Jayawardena, C. D. Pathiranage, A. Lionel, G. Constantine","doi":"10.15406/jdmdc.2018.05.00131","DOIUrl":"https://doi.org/10.15406/jdmdc.2018.05.00131","url":null,"abstract":"Zinc is an essential trace element that plays a vital role as a co-factor in enzyme action, cell membrane stabilization, gene expression and cell signaling [1]. It is also important in insulin action and carbohydrate metabolism [2]. Zinc is involved in the physiology of insulin at several stages; it is found in the insulin secretory granules and is known to participate in the insulin synthesis, stabilization of pro-insulin, insulin secretion, insulin sensitivity, and insulin degradation [3,4]. Zinc could also play a role in the pathogenesis of diabetes. Studies have shown that diabetes is accompanied by hypozincemia and hyperzincuria [5,6]. Zinc absorption is also know to be altered in patients with diabetes [7]. The altered Zinc absorption and hyperzincuria identified in patients with diabetes is an indication of either the fact that Zinc metabolism is altered as a result of diabetes or the altered Zinc metabolism plays a role in the pathogenesis of diabetes. Homeostasis of Zinc is thought to depend on absorption as well as excretion. Studies have shown that the Zinc ingested by healthy persons are eliminated in the feces (90%) and in urine (2–10%) [8]. Zinc is primarily absorbed from small intestine, duodenum and ileum [9]. The oral Zinc tolerance test was proved to be an acceptable method to study zinc absorption and excretion in humans [10]. Absorption and/ or excretion of Zinc may be altered in various pathological states, such as diabetes mellitus. Pre-diabetes is an intermediate state of hyperglycemia with glycaemic parameters above normal but below the threshold for the initiation of treatment for diabetes [11]. The pre-diabetic state is characterized by either impaired Volume 5 Issue 1 2018","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"131 1","pages":"09-13"},"PeriodicalIF":0.0,"publicationDate":"2018-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79630075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-22DOI: 10.15406/JDMDC.2018.5.00130
M. Biplab, Ravindra Shukla, A. Basu, A. Sinha, A. Maiti, Kingshuk Bhattacharjee
Karl Landsteiner first described the ABO blood group in 1900.1 Blood grouping is based on antigenic property of red blood cells (RBC). The major h10uman blood group system is ABO. The blood group of a person depends upon the presence or absence of two genes A and B. The majority of ABO determinants are expressed on the ends of long polylactosamine chains.2 The gene for ABO group is present on chromosome 9 and on chromosome 1 for Rh system. The ABO system consists of complex carbohydrate molecules. Ever since the discovery of blood groups in 1900, there have been efforts to discover a possible association between ABO and Rh blood groups and different diseases.3 Certain diseases show strong association with the ABO blood groups, notably, peptic ulcer is much higher in blood group O4 whereas stomach cancer,5 tumors of salivary glands6 are more frequent in blood group A individuals. Many reports have appeared in recent years suggesting an association between blood groups and diabetes mellitus.7 The etiology of diabetes mellitus is complex and appears to involve interactions of genetic, immunological and environmental factors.8 In fact, human chromosome 1q21-q23 showed well replicated linkage to type-2 diabetes mellitus.9
{"title":"Association of ABO blood groups with type-2 diabetes mellitus and its complications","authors":"M. Biplab, Ravindra Shukla, A. Basu, A. Sinha, A. Maiti, Kingshuk Bhattacharjee","doi":"10.15406/JDMDC.2018.5.00130","DOIUrl":"https://doi.org/10.15406/JDMDC.2018.5.00130","url":null,"abstract":"Karl Landsteiner first described the ABO blood group in 1900.1 Blood grouping is based on antigenic property of red blood cells (RBC). The major h10uman blood group system is ABO. The blood group of a person depends upon the presence or absence of two genes A and B. The majority of ABO determinants are expressed on the ends of long polylactosamine chains.2 The gene for ABO group is present on chromosome 9 and on chromosome 1 for Rh system. The ABO system consists of complex carbohydrate molecules. Ever since the discovery of blood groups in 1900, there have been efforts to discover a possible association between ABO and Rh blood groups and different diseases.3 Certain diseases show strong association with the ABO blood groups, notably, peptic ulcer is much higher in blood group O4 whereas stomach cancer,5 tumors of salivary glands6 are more frequent in blood group A individuals. Many reports have appeared in recent years suggesting an association between blood groups and diabetes mellitus.7 The etiology of diabetes mellitus is complex and appears to involve interactions of genetic, immunological and environmental factors.8 In fact, human chromosome 1q21-q23 showed well replicated linkage to type-2 diabetes mellitus.9","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"9 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2018-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78222819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-06DOI: 10.15406/JDMDC.2017.04.00127
Majumder Anirban, Bhattacharjee Kingshuk
Submit Manuscript | http://medcraveonline.com Keymessages: Clinicians may start with very low dose (0.2mg per day) liraglutide with subsequent weekly up-titration to minimize the gastrointestinal intolerance of liraglutide therapy, in obese and/or overweight Indian type 2 diabetes patients. Abbreviations: ADA: American Diabetes Association; BMI: Body Mass Index; DBP: Diastolic Blood Pressure; EASD: European Association for the Study of Diabetes; FPG: Fasting Plasma Glucose; GLP-1: Glucagon-Like Peptide-1; GI: Gastrointestinal; Volume 4 Issue 6 2017
{"title":"Beginning with very low dose (0.2mg) liraglutide in indian type 2 diabetic patients appears better tolerated: experience from real life practice","authors":"Majumder Anirban, Bhattacharjee Kingshuk","doi":"10.15406/JDMDC.2017.04.00127","DOIUrl":"https://doi.org/10.15406/JDMDC.2017.04.00127","url":null,"abstract":"Submit Manuscript | http://medcraveonline.com Keymessages: Clinicians may start with very low dose (0.2mg per day) liraglutide with subsequent weekly up-titration to minimize the gastrointestinal intolerance of liraglutide therapy, in obese and/or overweight Indian type 2 diabetes patients. Abbreviations: ADA: American Diabetes Association; BMI: Body Mass Index; DBP: Diastolic Blood Pressure; EASD: European Association for the Study of Diabetes; FPG: Fasting Plasma Glucose; GLP-1: Glucagon-Like Peptide-1; GI: Gastrointestinal; Volume 4 Issue 6 2017","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85122802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-09-15DOI: 10.15406/JDMDC.2017.04.00125
M. Cuenca
{"title":"Understanding the right to health and food for the type 2 diabetic patient","authors":"M. Cuenca","doi":"10.15406/JDMDC.2017.04.00125","DOIUrl":"https://doi.org/10.15406/JDMDC.2017.04.00125","url":null,"abstract":"","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"603 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77392119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-18DOI: 10.15406/jdmdc.2017.04.00124
Chi-En Lin, Mackenzie M. Honikel, J. LaBelle
Tight glycemic control has been the goal of care for people with diabetes [1], as achieving near-normal glucose levels has been shown to reduce the risk of microvascular disease [2-4]. Traditionally, people with diabetes are instructed to check their glucose consistently using self-monitoring of blood glucose (SMBG) technologies and make appropriate modifications to their medical intervention according to experience, empirically derived algorithms, and lifestyle. However, there are many challenges throughout the process including an increased risk of hypoglycemia when attempting to reach tighter glucose control. In addition, there is also a lack of ability to effectively account for multiple simultaneous life-style choices (e.g., exercise, alcohol ingestion, accurate carbohydrate counting) when deciding insulin boluses. These challenges all contribute to variability and unpredictability of daily glucose control. Unfortunately, sporadic measurement of glucose alone is insufficient to reach the goal of tight glycemic control, as it is merely a biomarker that reflects a series of complicated metabolism process. Given the discussed limitations there is a continued effort to improve glycemic management. Continuous monitoring and multi-marker detection are instrumental in achieving better management of the condition.
{"title":"A multi-marker approach for improved glycemic management in diabetes mellitus","authors":"Chi-En Lin, Mackenzie M. Honikel, J. LaBelle","doi":"10.15406/jdmdc.2017.04.00124","DOIUrl":"https://doi.org/10.15406/jdmdc.2017.04.00124","url":null,"abstract":"Tight glycemic control has been the goal of care for people with diabetes [1], as achieving near-normal glucose levels has been shown to reduce the risk of microvascular disease [2-4]. Traditionally, people with diabetes are instructed to check their glucose consistently using self-monitoring of blood glucose (SMBG) technologies and make appropriate modifications to their medical intervention according to experience, empirically derived algorithms, and lifestyle. However, there are many challenges throughout the process including an increased risk of hypoglycemia when attempting to reach tighter glucose control. In addition, there is also a lack of ability to effectively account for multiple simultaneous life-style choices (e.g., exercise, alcohol ingestion, accurate carbohydrate counting) when deciding insulin boluses. These challenges all contribute to variability and unpredictability of daily glucose control. Unfortunately, sporadic measurement of glucose alone is insufficient to reach the goal of tight glycemic control, as it is merely a biomarker that reflects a series of complicated metabolism process. Given the discussed limitations there is a continued effort to improve glycemic management. Continuous monitoring and multi-marker detection are instrumental in achieving better management of the condition.","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84041374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-18DOI: 10.15406/JDMDC.2017.04.00123
Larry Ellingson
because they are manufactured from known chemicals and are characterized by their chemical equivalence making them virtually identical to the original branded medication. However, Non-Medical Switching has now been extended to biologic medications, such as insulin. The manufacturing processes for insulin use different cell lines, protein sources, as well as extraction and purification techniques. These are proprietary and often patented processes. The insulins may have similar abilities to lower blood glucose but they are not identical replacements.
{"title":"Position on non-medical switching for diabetes patients","authors":"Larry Ellingson","doi":"10.15406/JDMDC.2017.04.00123","DOIUrl":"https://doi.org/10.15406/JDMDC.2017.04.00123","url":null,"abstract":"because they are manufactured from known chemicals and are characterized by their chemical equivalence making them virtually identical to the original branded medication. However, Non-Medical Switching has now been extended to biologic medications, such as insulin. The manufacturing processes for insulin use different cell lines, protein sources, as well as extraction and purification techniques. These are proprietary and often patented processes. The insulins may have similar abilities to lower blood glucose but they are not identical replacements.","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75020369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-16DOI: 10.15406/JDMDC.2017.04.00122
M. Herrera-Cuenca
The articles number eleven and twelve of the international covenant of economic, social and cultural rights state that it should be recognized the right of every human being to an adequate life standard for him/herself and their families, including food, dress and housing and to continuing improving their life conditions; as well as the right of every individual to the fulfillment of the best and highest possible standard of physical and mental health.3
{"title":"The right to food and health for patients: challenges of a world in crisis","authors":"M. Herrera-Cuenca","doi":"10.15406/JDMDC.2017.04.00122","DOIUrl":"https://doi.org/10.15406/JDMDC.2017.04.00122","url":null,"abstract":"The articles number eleven and twelve of the international covenant of economic, social and cultural rights state that it should be recognized the right of every human being to an adequate life standard for him/herself and their families, including food, dress and housing and to continuing improving their life conditions; as well as the right of every individual to the fulfillment of the best and highest possible standard of physical and mental health.3","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89738393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：